ubistesin 40 mg/ml + 0,005 mg/ml otopina za injekciju
pierrel s.p.a., strada statale appia 7bis, 46/48, capua (ce), italija - artikainklorid adrenalinklorid (epinefrinklorid) - otopina za injekciju - 40 mg/ml + 0,005 mg/ml - urbroj: 1 ml otopine za injekcije sadrži 40 mg artikainklorida i 0,005 mg epinefrina (adrenalin) u obliku epinefrinklorida
ubistesin forte 40 mg/ml + 0,01 mg/ml otopina za injekciju
pierrel s.p.a., strada statale appia 7bis, 46/48, capua (ce), italija - artikainklorid adrenalinklorid (epinefrinklorid) - otopina za injekciju - 40 mg/ml + 0,01 mg/ml - urbroj: 1 ml otopine za injekcije sadrži 40 mg artikainklorida i 0,01 mg epinefrina (adrenalin) u obliku epinefrinklorida
tecotherm neo sustav za hipotermiju sa jednokratnim setom sondi
mediva d.o.o. savska cesta 141 10000 zagreb -
3m steri drape isolation bag
medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -
valux™ plus restorative
clinres farmacija d.o.o. srebrnjak 61 10000 zagreb -
precise vista skin stapler 15 regular
medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -
bair hugger model 241 sustav za grijanje krvi/tekućina
medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -
spotontm temperature monitoring system control unit
medical intertrade d.o.o. dr. franje tuđmana 3 10431 sveta nedelja -
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitna, kronična, b-stanica - antineoplastična sredstva - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.